Infections represent an important cause of morbidity and mortality in cancer patients, especially those patients receiving intensive chemotherapy or undergoing stem cell transplant. The changing epidemiological patterns of infections in cancer patients are characterised not only by the increasing incidence of some opportunistic pathogens, but also by the wide emergence of resistance to antimicrobials, particularly in bacteria. The management of these complications has improved greatly during the past decades, especially in the field of antimicrobial prophylaxis. In the last few years, new antimicrobial drugs have been investigated, with the aim of defining new strategies for prophylaxis against bacterial, fungal and viral infections.
became more common, probably due to the increased use of venous catheters and systemic prophylaxis with fluoroquinolones, which can allow entry of, and colonisation by, gram-positive skin and intestinal flora. [4] [5] [6] [7] Currently, coagulase-negative staphylococci continue to be the most common blood isolates; however, the emergence of infections by Enterobacteriaceae (e.g., Escherichia coli and Klebsiella species) and non-fermenting gram-negative pathogens (e.g., Pseudomonas aeruginosa and Stenotrophomonas maltophilia) has been observed in several centres. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In particular, drug-resistant gram-negative bacteria species are causing an increasing number of infections in febrile neutropenic patients. Klebsiella species and E. coli strains with acquired extended-spectrum beta-lactamase (ESBL) genes frequently show a broad range greater need of mechanical ventilation (14 % versus 3 %, p=0.005) and had a higher overall case fatality rate (41 % versus 21 %, p=0.003).
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A very high rate of resistant gram-negative isolates in patients with haematological malignancies was observed in an Italian centre. 18 Out of 62 episodes of bacteraemia caused by E. coli, overall incidences of ESBL production and fluoroquinolone resistance were 41.9 % and 62.9 %, respectively. The overall 30-day mortality rate was 21 %. In a multivariate analysis, the significant predictors of mortality were inadequate initial antimicrobial therapy (odds ratio A prospective study of infections in nine Italian tertiary care centres or university hospitals among adult patients diagnosed with haematological malignancies was started in 2009. 19 The analysis of patients with P. aeruginosa bacteraemias showed 71 % MDR strains.
In particular, the percentages of resistance to carbapenems (imipenem and meropenem), anti-pseudomonal cephalosporins (ceftazidime and cefepime), amikacin and ciprofloxacin were 60 %, 42 %, 50 % and 66 %, respectively, whereas the percentage of resistance to piperacillin was 24 %. Mortality within 30 days of the first positive blood culture occurred in 40 % of MDR P. aeruginosa bacteraemias and in 9 % of non-MDR P. aeruginosa bacteraemias. In a multivariate analysis, inadequate initial antibacterial therapy was independently associated with mortality (p=0.006).
All these studies show the increasing epidemiological burden of severe infections by resistant bacterial pathogens. A crucial problem in the management of such infections is the choice of prophylaxis and initial antibacterial therapy, considering that it may dramatically affect the outcomes of such complications. A continuous microbiological survey at each cancer centre is required to monitor the trend of resistant micro-organisms and to guide the use of antimicrobials.
Fungal Infections
IFDs, especially those caused by Candida and Aspergillus species, historically represent a major cause of death in cancer patients, especially after intensive chemotherapy and receipt of SCT.
However, a continuous modification in epidemiology and outcomes has been observed over the last decades, as a result of prevention strategies and changes in host characteristics and treatment modalities.
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Another factor that may greatly impact on • Norfloxacin: 400 mg bid oral -less effective than ciprofloxacin (BI)
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• Ofloxacin: 200-300 mg bid oral -less tested than ciprofloxacin in randomised controlled trials and at variable daily doses, lower activity against P. aeruginosa and less effective than ciprofloxacin (BI)
Antifungal Prophylaxis
Leukaemia patients, • Echinocandins (insufficient data)
• Polyenes: IV (CI)
• Aerosolised liposomal AmB plus fluconazole (insufficient data)
Antiviral Prophylaxis
Herpes simplex virus (HSV) Antiviral drug prophylaxis is not recommended in HSV-seronegative leukaemic patients during chemotherapy or after SCT (DIII).
HSV-seropositive patients undergoing allogeneic HSCT for acute leukaemia should receive antiviral drug prophylaxis (AI).
HSV-seropositive patients treated for acute leukaemia by chemotherapy alone should be considered for antiviral drug prophylaxis (BIII). Intravenous (5 mg/kg q12h) or oral acyclovir (from 3 x 200 mg/day to 2 x 800 mg/day) (AI) or oral valaciclovir (2 x 500 mg/day) (BIII) should be given prophylactically for three to five weeks after start of chemotherapy or after allogeneic SCT, and for longer periods of time in children treated for acute leukaemia. Allogeneic SCT recipients who develop GVHD or receive immunosuppressive treatment, including steroids, usually require prolonged HSV prophylaxis (BII)
Varicella zoster virus (VZV) Passive immunisation with IV VZIG (0.2-1 ml/kg) or IM ZIG or IVIG (300-500 mg/kg) should be given within 96 hours after exposure to VZV-seronegative leukaemic patients on chemotherapy and patients receiving steroids, as well as to VZV-seronegative SCT recipients, patients who have chronic GVHD, patients who are on immunosuppressive treatment, and patients who received SCT within the past two years (AII). Where passive immunisation is not available, post-exposure prophylaxis with aciclovir (800 mg four times daily; 600 mg/m 2 four times daily for children), valaciclovir (1,000 mg tid; 500 mg tid for <40 kg body weight) or famciclovir (500 mg tid) is recommended, starting within 3 days of exposure and continuing for 21 days (AIII). If a second exposure occurs more than 21 days after a dose of passive immunisation or after the administration of the antiviral prophylaxis, a prophylaxis should be readministered (CIII).
Prophylaxis in VZV-seropositive patients is optional (CIII). Determination of VZV immunoglobulin serostatus before transplant is recommended for all SCT candidates (AIII). Prophylaxis with oral acyclovir (800 mg bid) or valaciclovir (500 mg od or bid) is recommended for seropositive allogeneic SCT recipients for one year (AII) or longer in the presence of GVHD and immunosuppressive therapy (BII). Prophylaxis in autologous SCT is controversial Cytomegalovirus (CMV) A pre-emptive antifungal strategy based on the monitoring of CMV infection by antigenaemia and quantitative PCR represents the most widely used approach, not only in the allogeneic SCT setting but also in other categories at risk of CMV infection and disease, such as patients with chronic lymphocytic leukaemia under alemtuzumab therapy. Antiviral chemoprophylaxis is an alternative to pre-emptive therapy in subgroups of patients at high risk of CMV disease. Intravenous ganciclovir prophylaxis is an effective strategy for the prevention of CMV disease and could be used in subgroups of allogeneic SCT patients at high risk of CMV disease (BI).
Aciclovir or valaciclovir can be used as prophylaxis against CMV in allogeneic SCT patients (BI). However, their use must be combined with monitoring and pre-emptive therapy (AI). Immunoglobulin has no role as prophylaxis against CMV infection (EII). Valganciclovir prophylaxis is effective and reduces the risk of symptomatic CMV infection in patients receiving alemtuzumab (BII) Table 2 for an explanation of the grading system adopted for the recommendations. For fungi also does the reduced susceptibility to antifungal drugs represent a challenging problem. The phenomenon of Candida species resistance to triazoles has been largely reported for fluconazole and itraconazole since their first use more than two decades ago, and it continues to be an important issue for the second-generation triazoles posaconazole and voriconazole.
AmB = amphotericin B; bid = twice daily; GVHD = graft-versus-host disease; HSCT = haematopoietic stem cell transplant; IM = intramuscular; IV = intravenous; IVIG = intravenous immunoglobulin; od = once daily; PCR = polymerase chain reaction; q12h = every 12 hours; qd = each day; SCT = stem cell transplant; tid = three times daily; VZIG = varicella zoster immunoglobulin; ZIG = zoster immunoglobulin. See notes at the bottom of
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Resistance to triazoles has also been observed for Aspergillus species in some European countries, although, according to multinational surveys, the phenomenon seems uncommon. An in vitro study of 
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Prophylaxis Against Infections in Cancer and Stem Cell Transplant Patients
Until recently, the impact of prophylaxis against infections in cancer patients had been controversial, but new data now suggests that chemoprophylaxis might be able not only to reduce the incidence of infectious complications, but also to allow the continuation of treatment of the underlying malignancy, with a possible impact on long-term overall survival. Current European and US guidelines on antibacterial, antifungal and antiviral prophylaxis have been summarised in Table 1 and Table 2 , respectively.
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Antibacterial Prophylaxis
The risk of bacterial infection is directly related to the severity and duration of neutropenia 
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Posaconazole and voriconazole -second-generation triazoles with a broad spectrum of activity -have been compared with fluconazole or itraconazole in phase III clinical trials of prophylaxis in leukaemia and SCT patients. [63] [64] [65] [66] Posaconazole prophylaxis was associated with a significantly lower rate of invasive aspergillosis, both in neutropenic Neutropenia and Infections
patients with acute myeloid leukaemia and in allogeneic SCT recipients with graft-versus-host disease (GVHD), but only in the leukaemia setting did patients who received posaconazole prophylaxis experience a significantly longer survival. 63, 64 Two controlled studies of primary antifungal prophylaxis with voriconazole have been conducted in allogeneic SCT patients. 65, 66 In the first study, in which voriconazole was compared with fluconazole, only a trend towards fewer Aspergillus infections was observed with voriconazole, and the fungal-free survival (primary endpoint of the study) was similar in the two groups. 65 However, it should be considered that, in the subgroup of patients with acute myeloid leukaemia -a population at higher risk of infection -voriconazole significantly reduced IFDs and improved fungal-free survival compared with fluconazole. 70 In the second study, voriconazole was superior to itraconazole considering a primary composite endpoint that included efficacy and tolerability criteria; however, no difference in the incidence of IFDs was observed in the two arms, probably due to the overall low rate of infections observed in the study. subgroups of cancer patients may be high, but the risk of evolution to CMV disease is very low; therefore routine surveillance is unnecessary and prophylaxis not recommended in these patients.
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As an alternative to pre-emptive therapy, IV ganciclovir prophylaxis is an effective strategy for the prevention of CMV disease in subgroups of allogeneic SCT patients at high risk of CMV disease, but acyclovir or valaciclovir at high doses can also be used. In any case, their use must be combined with monitoring and a pre-emptive approach. 
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before cancer treatment is initiated. 77 Controlled clinical trials and several subsequent meta-analyses have shown that prophylaxis with nucleoside analogues (e.g., lamivudine) decreases the incidence of HBV reactivation and the frequency of clinical hepatitis and death from HBV-associated liver injury in patients undergoing chemotherapy or SCT. [78] [79] [80] [81] [82] [83] [84] Such therapy should be commenced before the start of chemotherapy or before transplant and should be continued for at least six months after the end of chemotherapy, or for longer in case of long-term immune suppression. 
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Conclusions
